US › Healthcare

Innate Pharma (IPHA)

US · Healthcare · Biotechnology

$1.91-4.98%

Last close · 2026-09-17

Latest quarter · ended 2026-03-31

Revenue

$-2.1M

Revenue YoY

-116.8%

Net profit

$-27.6M

EPS

$0.00

EPS estimate

$-0.16

EPS came in at 0.00 against a street estimate of -0.16 — a beat of 100.0%.

Key statistics

Market cap

$224.5M

Forward P/E

0.0

P/B

20.10

Book value

$-0.27

EPS (TTM)

$-0.69

52-week high

$2.71

52-week low

$1.17

50-day MA

$1.96

200-day MA

$1.75

Beta

0.88

Analyst view

Analysts rate Innate Pharma a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $6.67.

Shareholding

Insiders

1.40%

Institutions

0.39%

Largest institutional holders

Fund	Stake
Lion Point Capital, LP	0.07%
Morgan Stanley - Brokerage Accounts	0.04%
Jane Street Group LLC	0.04%
SmartHarvest Portfolios, LLC	0.02%
Citadel Advisors Llc	0.01%
Rhumbline Advisers	0.00%
UBS Group AG	0.00%
GAMMA Investing LLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Innate Pharma — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.